ASTRAZEN

AstraZeneca Pharma India Share Price

₹9,127.00 -23.5 (-0.26%)

08 Jul, 2025 21:07

SIP TrendupStart SIP in ASTRAZEN

Start SIP

Performance

  • Low
  • ₹9,060
  • High
  • ₹9,260
  • 52 Week Low
  • ₹6,220
  • 52 Week High
  • ₹10,691
  • Open Price₹9,150
  • Previous Close₹9,151
  • Volume31,963

Investment Returns

  • Over 1 Month -6.77%
  • Over 3 Month + 15.99%
  • Over 6 Month + 28.76%
  • Over 1 Year + 32.36%
SIP Lightning

Smart Investing Starts Here Start SIP with AstraZeneca Pharma India for Steady Growth!

Invest Now

AstraZeneca Pharma India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 197.1
  • PEG Ratio
  • -7
  • Market Cap Cr
  • 22,818
  • P/B Ratio
  • 33.6
  • Average True Range
  • 295.94
  • EPS
  • 70.02
  • Dividend Yield
  • 0
  • MACD Signal
  • 48.38
  • RSI
  • 51.21
  • MFI
  • 54.31

AstraZeneca Pharma India Financials

AstraZeneca Pharma India Technicals

EMA & SMA

Current Price
₹9,127.00
-23.5 (-0.26%)
pointer
  • stock-down_img
  • Bearish Moving Average 2
  • stock-up_img
  • Bullish Moving Average 14
  • 20 Day
  • ₹9,116.76
  • 50 Day
  • ₹8,890.71
  • 100 Day
  • ₹8,458.48
  • 200 Day
  • ₹7,833.37

Resistance and Support

9149 Pivot Speed
  • R3 9,438.00
  • R2 9,349.00
  • R1 9,238.00
  • S1 9,038.00
  • S2 8,949.00
  • S3 8,838.00

What's your outlook on AstraZeneca Pharma India?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

AstraZeneca Pharma India Ltd. is a global, science-led pharmaceutical company dedicated to transforming healthcare through innovative medicines in oncology, biopharmaceuticals, and rare diseases. it focuses on improving patient outcomes and advancing healthcare worldwide.

Astrazeneca Pharma India has an operating revenue of Rs. 1,716.29 Cr. on a trailing 12-month basis. An annual revenue growth of 32% is outstanding, Pre-tax margin of 9% is okay, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 18% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around -0% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 65 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

AstraZeneca Pharma India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-30 Audited Results & Dividend
2025-02-11 Quarterly Results
2024-11-13 Quarterly Results
2024-08-08 Quarterly Results
2024-05-27 Audited Results & Dividend
Date Purpose Remarks
2024-07-05 FINAL Rs.24.00 per share(1200%)Dividend
2023-07-14 FINAL Rs.16.00 per share(800%)Dividend
2022-07-08 FINAL Rs.8.00 per share(400%)Final Dividend
2021-08-20 INTERIM Rs.2.00 per share(100%)Interim Dividend
View More

AstraZeneca Pharma India F&O

AstraZeneca Pharma India Shareholding Pattern

75%
4.45%
0.16%
2.89%
0%
15.15%
2.35%

About AstraZeneca Pharma India

  • NSE Symbol
  • ASTRAZEN
  • BSE Symbol
  • 506820
  • ISIN
  • INE203A01020

Similar Stocks to AstraZeneca Pharma India

AstraZeneca Pharma India FAQs

AstraZeneca Pharma India share price is ₹9,127 As on 08 July, 2025 | 20:53

The Market Cap of AstraZeneca Pharma India is ₹22817.5 Cr As on 08 July, 2025 | 20:53

The P/E ratio of AstraZeneca Pharma India is 197.1 As on 08 July, 2025 | 20:53

The PB ratio of AstraZeneca Pharma India is 33.6 As on 08 July, 2025 | 20:53

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23